Life Science Leader Chief Editor Blog Header image
The Drug Pricing Dilemma, Pfizer, And President Trump
An op-ed regarding Pfizer’s drug-pricing actions, President Trump, and the potential impact on the biopharmaceutical industry’s image. Continue Reading..
At The End Of The Day — And Other Phrases That Could Be Used Less
A review of buzzwords and phrases that should be used less in the world of business. Continue Reading..
BIO 2018 — A View Through The Eyes Of An Aspiring Biomedical Engineer
Miriam Massaad, a biomedical engineering student at Boston University, shares her experiences as a first-time attendee at the 2018 BIO International Convention and Conference in Boston. Continue Reading..
What Is MassBio Doing To Promote Greater Diversity And Inclusion?
Robert Coughlin, president and CEO of MassBio, discusses his organization’s approach to diversity and inclusion. Continue Reading..
Research Into The State Of Innovation In Highly Prevalent Chronic Diseases
Dave Thomas, managing director for industry research and analysis at the Biotechnology Innovation Organization (BIO), discusses chronic disease research and other industry trends. Continue Reading..
The Scientist Mentoring And Diversity Program — An Inside View From A Current Scholar
Shaness Grenald, Ph.D., a postdoctoral fellow in the department of anesthesiology and critical care medicine at Johns Hopkins University, discusses the Scientist Mentoring and Diversity Program (SMDP) at the 2018 BIO Buzz Center in Boston. Continue Reading..
Is The Open Office Concept An Idea That Should Have Been Killed?
Rob Wright discusses the open office concept, and if it is an idea that should be killed. Continue Reading..
A Testament To Biopharma’s Transparent Leaders: And A Previously Unpublished Regeneron Article Sidebar
Rob Wright discusses the unusual genesis of the Regeneron Genetics Center (RGC). Continue Reading..